Absolute and Fractional Donor‐Derived Cell‐Free DNA in the Follow‐Up of Kidney Allograft Rejection
HLA · 2026-04 · 107 (4)
DOI: 10.1111/tan.70709 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, online erschienen am 13.04.2026. Verfasst von Vojtech Petr und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Tissue Donors. Die Arbeit nennt 17 Literaturangaben. Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, European Union, Natera.
Abstract (Originalsprache)
Donor‐derived cell‐free DNA (dd‐cfDNA) is an emerging tool for noninvasive kidney allograft pathology diagnostics. However, its utility in anti‐rejection treatment follow‐up remains to be established. We measured dd‐cfDNA in 41 kidney transplant recipients (KTRs) at biopsy demonstrating rejection and then weekly for 3 weeks (155 samples). Biopsies were assessed by a pathologist (Banff 2022) and by Molecular Microscope Diagnostic System (MMDx), all KTRs received antirejection therapy. We found that dd‐cfDNA fraction decreased in most KTRs after treatment. However, absolute dd‐cfDNA decreased significantly only in those treated for T cell‐mediated rejection (77 copies/mL [cp/mL] at biopsy, 35 cp/mL at week 3), while there was no significant decrease (93 cp/mL at biopsy, 73 cp/mL at week 3) in patients with antibody‐mediated rejection (ABMR). Furthermore, we found that absolute dd‐cfDNA did not decrease in KTRs treated with plasma exchange. Finally, there was an unanticipated increase of total cell‐free DNA (cfDNA) in all KTRs after treatment. In conclusion, dd‐cfDNA follow‐up assessments may be confounded by treatment‐induced increase of total cfDNA. Thus, absolute dd‐cfDNA concentrations, in addition to fraction, might provide more complete information about the response to anti‐rejection treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Transplantation Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Department of Data Science, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
ORCID-Profile: Vojtech Petr, Ondrej Viklicky
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
- European Union
- Natera
- European Commission
Zitieren
APA
Petr, V., Hruba, P., Hruby, F., Voska, L., Schmalz, M., Chytilova, S., Hanzal, V., Zahradka, I., Slavcev, A., & Viklicky, O. (2026). Absolute and Fractional Donor‐Derived Cell‐Free DNA in the Follow‐Up of Kidney Allograft Rejection. HLA, 107(4). https://doi.org/10.1111/tan.70709
Vancouver
Petr V, Hruba P, Hruby F, Voska L, Schmalz M, Chytilova S, et al. Absolute and Fractional Donor‐Derived Cell‐Free DNA in the Follow‐Up of Kidney Allograft Rejection. HLA. 2026;107(4). doi:10.1111/tan.70709
BibTeX
@article{Petr2026,
author = {Petr, Vojtech and Hruba, Petra and Hruby, Filip and Voska, Ludek and Schmalz, Michal and Chytilova, Sarka and Hanzal, Vladimir and Zahradka, Ivan and Slavcev, Antonij and Viklicky, Ondrej},
title = {Absolute and Fractional Donor‐Derived Cell‐Free DNA in the Follow‐Up of Kidney Allograft Rejection},
journal = {HLA},
year = {2026},
volume = {107},
number = {4},
doi = {10.1111/tan.70709}
}
EUVIMED